In this review, we focus on specific histopathological markers, particularly CD169 macrophages, neuropilin-1, cofilin-1, interleukin-17, signal transducer and activator of transcription protein 3 (STAT3), LIM domain kinase 1 (LIMK1), prostate-specific membrane antigen (PSMA), Appl1, Sortilin, Syndecan-1, AMACR, CD15, and p63, which in the future may help to establish the prognosis of patients with PCa as well as assist in choosing the most beneficial adjuvant therapy. This evidence concerns the gene NRP1 and posterior cortical atrophy.